Qrons Inc. has established a collaboration with scientists at a public research university in Israel, by which Tellurium-based compounds in combination with Qrons' QS-200 product candidate and other configurations will be explored as treatment for diffused axonal injuries (concussions), which accounts for approximately 89% of traumatic brain injuries (TBIs).

Everest Medicines Ltd. has achieved a preclinical proof-of-concept milestone for its mRNA rabies vaccine program. This new vaccine candidate for rabies post-exposure prophylaxis was developed in partnership with Providence Therapeutics Holdings Inc. utilizing a clinically validated mRNA technology platform.

The HIV regulatory protein transactivator of transcription (Tat) is a viral protein believed to play a key role in the neurotoxicity and cognitive impairment seen in HIV-associated neurocognitive disorders. Tat allosterically modulates dopamine (DA) reuptake through the human DA transporter (hDAT). In the current study, researchers from University of South Carolina and affiliated organizations aimed to assess the effects of the novel allosteric modulator of DAT, SRI-32743, on the Tat-DAT interaction.

Abata Therapeutics Inc. has selected its first development candidate, ABA-101, an autologous regulatory T cell (Treg) therapy for the treatment of progressive multiple sclerosis (MS). ABA-101 targets MS patients with nonrelapsing progressive disease who have a DRB1*15:01 genetic haplotype and for whom imaging evidence of ongoing inflammatory tissue injury has been observed.